AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $52.2222.

A number of research analysts recently issued reports on ATRC shares. Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Canaccord Genuity Group boosted their target price on shares of AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $36.12 on Friday. AtriCure has a one year low of $28.29 and a one year high of $43.11. The stock has a market cap of $1.80 billion, a PE ratio of -59.21 and a beta of 1.56. The business’s fifty day moving average price is $35.12 and its two-hundred day moving average price is $34.29. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. During the same period last year, the company posted ($0.17) EPS. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, analysts forecast that AtriCure will post -0.6 EPS for the current fiscal year.

Insider Transactions at AtriCure

In other news, Director Maggie Yuen sold 3,000 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $35.72, for a total transaction of $107,160.00. Following the completion of the sale, the director directly owned 11,371 shares of the company’s stock, valued at $406,172.12. This represents a 20.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Sven Wehrwein sold 4,967 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total value of $188,746.00. Following the completion of the transaction, the director owned 34,374 shares of the company’s stock, valued at $1,306,212. This trade represents a 12.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,166 shares of company stock valued at $785,278 in the last three months. 3.50% of the stock is currently owned by corporate insiders.

Institutional Trading of AtriCure

A number of hedge funds have recently bought and sold shares of the company. Oberweis Asset Management Inc. purchased a new position in shares of AtriCure in the third quarter worth approximately $5,411,000. Voloridge Investment Management LLC boosted its stake in AtriCure by 1.5% in the 3rd quarter. Voloridge Investment Management LLC now owns 273,749 shares of the medical device company’s stock worth $9,650,000 after purchasing an additional 4,041 shares during the period. Verition Fund Management LLC grew its position in AtriCure by 126.8% during the 3rd quarter. Verition Fund Management LLC now owns 17,752 shares of the medical device company’s stock worth $626,000 after purchasing an additional 9,924 shares in the last quarter. Qube Research & Technologies Ltd grew its position in AtriCure by 203.6% during the 3rd quarter. Qube Research & Technologies Ltd now owns 94,729 shares of the medical device company’s stock worth $3,339,000 after purchasing an additional 63,531 shares in the last quarter. Finally, Focus Partners Wealth raised its stake in AtriCure by 10.1% during the 3rd quarter. Focus Partners Wealth now owns 19,880 shares of the medical device company’s stock valued at $691,000 after purchasing an additional 1,824 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.